Consistently, NVP-BEZ235-treated MCL samples downregulated well-known pathways affected by PI3K/Akt/mTOR inhibitors.[2] In addition, we observed inhibition of pathways involved in angiogenesis, cell invasion and inflammation processes. The gene discussed is MTOR; the disease is mantle cell lymphoma.